Two-Tiered Lab Tests Miss More Than 50% Of The Cases Of Lyme Disease
Two-Tiered lab tests miss more than 50% of the cases of Lyme disease and are no better than a coin toss. Dr. Stricker and Lorraine Johnson published an article that contains a table listing the results of different studies regarding lab sensitivity.
Lyme disease diagnosis and treatment: Lessons from the AIDS epidemic.
This article is behind a paywall, but the blog post shown below summarizes the state of lab tests and recreates the lab insensitivity table.
Tests can be helpful not only to diagnose a disease, but also to manage an illness. A good test can help a doctor assess the severity of disease, estimate the patient’s prognosis, monitor the course of disease progression, stability or resolution, detect relapse, and select drugs or adjust therapy. Unfortunately, no test with this capability exists for Lyme disease.
The most common tests for Lyme disease measure the patient’s antibody response to infection. When your body is invaded by the Lyme spirochetes, your immune system makes antibodies to fight the infection. Tests that measure antibody levels are indirect tests. They measure the body’s immune response to infection rather than the actual presence of bacteria.
The Centers for Disease Control recommends two-tiered antibody testing for Lyme disease. The first step is an ELISA test. If positive, it is followed up with a Western blot. The CDC recommends two-tiered tests for HIV/AIDS as well. However, the AIDS two-tiered tests have a sensitivity of 99.5%, meaning that they catch nearly every case. Unfortunately, in Lyme disease the two-tiered approach has a sensitivity of less than 50%, meaning that it misses more than half of the cases.
(The chart above is adapted from Stricker, R. and Johnson, L., Lyme disease diagnosis and treatment: Lessons from the AIDS epidemic. Minerva Med. 2010; 101: 419-25.)
There are a number of reasons for the difference. The most important one is that the current ELISA tests are not sensitive enough for screening. Studies by the College of American Pathologists (CAP) concluded that the currently available ELISA tests for Lyme do not have adequate sensitivity to meet the two-tiered approach recommended by the CDC for surveillance.
In his research, Dr. Sam Donta has observed that 52% of patients with chronic Lyme disease are found negative by ELISA but positive by Western blot. This corresponds with the published findings of LymeDisease.org’s survey of over 5,000 patients with chronic Lyme disease. The survey found that 30% of patients were diagnosed by two-tiered serology and 24% were diagnosed by Western blot alone.
After years of patient complaints regarding the two-tiered testing system, the Council of State and Territorial Epidemiologists revised the CDC surveillance system to permit stand-alone Western blots. However, according to CDC representative Paul Mead’s recent remarks on testing, the agency still endorses two-tiered testing for Lyme. But even Western blots have their challenges.
The CDC acknowledges that laboratory tests in early Lyme disease, before antibodies are developed by the patient, are very unreliable. However, the CDC contends that in late Lyme disease, the two-tiered testing is 100% sensitive. But it bases this claim on a study of exactly 11 patients with late neurologic Lyme disease. And, get this, in order to enroll in the study, the patients had to first test positive. So everyone who tested positive to get in the study then tested positive again. (That, by the way, is called circular reasoning.)
We need a little less rhetoric from the CDC and a lot more emphasis on improving testing so that sick patients can get better.
The LYME POLICY WONK blog is written by Lorraine Johnson, JD, MBA, who is the Chief Executive Officer of LymeDisease.org, formerly CALDA. Contact her at firstname.lastname@example.org. On Twitter, follow me @lymepolicywonk
Bacon RM, Biggerstaff BJ, Schriefer ME, Gilmore RD, Jr., Philipp MT, Steere AC, et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. The Journal of Infectious Diseases. 2003 Apr 15;187(8):1187-99.
Bakken LL, Callister SM, Wand PJ, Schell RF. Interlaboratory comparison of test results for detection of Lyme disease by 516 participants in the Wisconsin State Laboratory of Hygiene/College of American Pathologists Proficiency Testing Program. J. Clin. Microbiol. 35(3), 537–543 (1997).
Donta ST. Late and chronic Lyme disease. Med. Clin. North Am. 86(2), 341–349 (2002).
Stricker, R. and Johnson, L., Lyme disease diagnosis and treatment: Lessons from the AIDS epidemic. Minerva Med. 2010; 101: 419-25.
Centers for Disease Control and Prevention (CDC). Lyme Disease (Borrelia burgdorferi): 2008 Case Definition. http://www.cdc.gov/ncphi/disss/nndss/casedef/lyme_disease_2008.htm.
Johnson L, Wilcox S, Mankoff J, Stricker RB. Severity of chronic Lyme disease compared to other chronic conditions: a quality of life survey. PeerJ. 2014 2014/03/27;2:e322. https://peerj.com/articles/322/